BDB
BDB (1,3-benzodioxolylbutanamine) is the primary-amine, alpha-ethyl homolog of MDA and the N-desmethyl counterpart of MBDB. It is a serotonin-selective entactogen studied by David Nichols, producing MDMA-like emotional openness with minimal stimulation and little euphoria. Human data are minimal.
01 Overview
BDB, along with its N-methyl homolog MBDB, was used in academic research to define the entactogen class as distinct from stimulants and psychedelics. It reliably produces gentle emotional relaxation with weak reward, often described as subtle.
Beyond early exploratory work, human data are scarce. Its serotonin-releasing action carries theoretical neurotoxicity and serotonin-syndrome risk. It is controlled or analog-covered in many jurisdictions.
02 Mechanism
Alpha-ethyl benzodioxole acting as a relatively serotonin-selective releasing agent at the serotonin transporter with weak dopamine activity.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 100–150 mg | Oral | Threshold-to-light |
| Common | 150–250 mg | Oral | Less potent than MDMA by weight |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Emotional relaxationGentle openness and calm with little euphoria. | Mild-moderate | Anecdotal | |
| Minimal stimulationSubtle profile with little of MDMA's drive. | Minimal | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeSerotonin release can precipitate serotonin toxicity in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Observational | |
| Serotonergic neurotoxicitySerotonin-releasing entactogens carry theoretical axonal neurotoxicity as with MDMA. | Severe | Theoretical | Preclinical | |
| BruxismJaw clenching typical of serotonin releasers. | Mild | Common | Anecdotal |